Valicenti Advisory Services Inc. grew its position in shares of Zoetis Inc (NYSE:ZTS) by 0.8% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 23,664 shares of the company’s stock after purchasing an additional 195 shares during the period. Valicenti Advisory Services Inc.’s holdings in Zoetis were worth $3,132,000 at the end of the most recent quarter.
Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Nuveen Asset Management LLC grew its position in Zoetis by 40,874.9% in the second quarter. Nuveen Asset Management LLC now owns 7,078,826 shares of the company’s stock worth $803,376,000 after acquiring an additional 7,061,550 shares in the last quarter. Stonehage Fleming Financial Services Holdings Ltd acquired a new stake in shares of Zoetis during the second quarter worth about $133,113,000. Natixis lifted its position in shares of Zoetis by 147.1% during the second quarter. Natixis now owns 547,078 shares of the company’s stock worth $62,088,000 after purchasing an additional 325,661 shares in the last quarter. California Public Employees Retirement System lifted its position in shares of Zoetis by 12.0% during the third quarter. California Public Employees Retirement System now owns 2,397,369 shares of the company’s stock worth $298,688,000 after purchasing an additional 256,715 shares in the last quarter. Finally, CIBC Private Wealth Group LLC lifted its position in shares of Zoetis by 9.9% during the third quarter. CIBC Private Wealth Group LLC now owns 2,356,999 shares of the company’s stock worth $293,659,000 after purchasing an additional 212,112 shares in the last quarter. Hedge funds and other institutional investors own 89.93% of the company’s stock.
In related news, EVP Clinton A. Jr. Lewis sold 6,123 shares of the firm’s stock in a transaction dated Thursday, November 14th. The stock was sold at an average price of $116.13, for a total transaction of $711,063.99. Following the completion of the transaction, the executive vice president now owns 36,584 shares of the company’s stock, valued at $4,248,499.92. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Kristin C. Peck sold 11,500 shares of the company’s stock in a transaction on Tuesday, November 12th. The shares were sold at an average price of $117.16, for a total value of $1,347,340.00. Following the sale, the executive vice president now directly owns 44,877 shares of the company’s stock, valued at $5,257,789.32. The disclosure for this sale can be found here. Over the last quarter, insiders sold 126,116 shares of company stock worth $15,099,357. 0.29% of the stock is currently owned by insiders.
Several brokerages have recently issued reports on ZTS. Raymond James began coverage on shares of Zoetis in a research report on Thursday, January 9th. They set a “market perform” rating on the stock. ValuEngine cut shares of Zoetis from a “buy” rating to a “hold” rating in a report on Wednesday, October 2nd. Morgan Stanley raised their price objective on shares of Zoetis from $100.00 to $136.00 and gave the stock an “equal weight” rating in a report on Monday, September 30th. Credit Suisse Group set a $138.00 price objective on shares of Zoetis and gave the stock a “buy” rating in a report on Friday, October 11th. Finally, Bank of America reissued a “hold” rating and set a $125.00 price objective on shares of Zoetis in a report on Thursday, December 5th. Eight research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company. The company has an average rating of “Buy” and an average target price of $127.47.
ZTS stock opened at $140.16 on Tuesday. The company has a current ratio of 4.39, a quick ratio of 3.02 and a debt-to-equity ratio of 2.47. Zoetis Inc has a twelve month low of $82.80 and a twelve month high of $140.40. The company’s 50 day moving average is $130.72 and its two-hundred day moving average is $124.10. The stock has a market cap of $66.76 billion, a P/E ratio of 46.26, a PEG ratio of 3.04 and a beta of 0.81.
Zoetis (NYSE:ZTS) last announced its earnings results on Thursday, November 7th. The company reported $0.94 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.88 by $0.06. The business had revenue of $1.58 billion for the quarter, compared to analyst estimates of $1.58 billion. Zoetis had a net margin of 23.76% and a return on equity of 70.78%. The company’s revenue for the quarter was up 7.0% compared to the same quarter last year. During the same period last year, the firm posted $0.83 earnings per share. On average, equities research analysts predict that Zoetis Inc will post 3.6 earnings per share for the current year.
The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 3rd. Investors of record on Friday, January 17th will be given a $0.20 dividend. This represents a $0.80 dividend on an annualized basis and a yield of 0.57%. This is a positive change from Zoetis’s previous quarterly dividend of $0.16. The ex-dividend date of this dividend is Thursday, January 16th. Zoetis’s dividend payout ratio (DPR) is 25.56%.
Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.
Featured Article: What is the Euro STOXX 50 Index?
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.